0000950170-24-080961.txt : 20240702 0000950170-24-080961.hdr.sgml : 20240702 20240702193003 ACCESSION NUMBER: 0000950170-24-080961 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240701 FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Michaelson Jennifer CENTRAL INDEX KEY: 0001838061 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 241097858 MAIL ADDRESS: STREET 1: C/O CULLINAN MANAGEMENT, INC. STREET 2: ONE MAIN STREET SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Therapeutics, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, Inc. DATE OF NAME CHANGE: 20210225 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 ownership.xml 4 X0508 4 2024-07-01 0001789972 Cullinan Therapeutics, Inc. CGEM 0001838061 Michaelson Jennifer C/O CULLINAN THERAPEUTICS, INC. ONE MAIN STREET, SUITE 1350 CAMBRIDGE MA 02142 false true false false Chief Scientific Officer false Common Stock 2024-07-01 4 A false 2360 9.00 A 131942 D The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2024. /s/ Jacquelyn Sumer, Attorney-in-Fact 2024-07-02